MedTrace Logo

Analysis of the Potential Savings of Rivaroxaban Events Versus Vitamin K Antagonists Events

NCT03462446 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 249

Last updated 2018-03-12

No results posted yet for this study

Summary

The main objective of this project is to evaluate savings in direct costs as regards the use of rivaroxaban versus vitamin K antagonists (VKAs) in routine clinical practice using data from three cohorts of patients receiving VKAs or rivaroxaban in Spain, including the time in therapeutic range (TTR) values of the same and the incidence of events in the first year following diagnosis.

Conditions

Interventions

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

As prescribed by treating physicians

DRUG

Vitamin K antagonists (VKAs)

As prescribed by treating physicians. VKAs are Acenocoumarol and Warfarin.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    collaborator INDUSTRY

  • Bayer

    lead INDUSTRY

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-01
Primary Completion
2016-05-01
Completion
2016-05-01

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03462446 on ClinicalTrials.gov